Akebia Therapeutics, Inc. products

As part of our mission, we’re working to address complications of kidney disease and we currently market AURYXIA (ferric citrate) in the U.S. for its two approved indications: The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis; The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.